ketoconazole has been researched along with indinavir sulfate in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (16.67) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 13 (43.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Choo, EF; Imamura, H; Kim, RB; Leake, B; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Guengerich, FP; Isin, EM | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Balani, SK; Chiba, M; Hensleigh, M; Lin, JH; Nishime, JA | 1 |
| Collins, JM; Fitzsimmons, ME | 1 |
| Haddix, HM; Matuszewski, B; Woolf, E | 1 |
| Gangl, E; Gerber, N; Iatsimirskaia, E; Koudriakova, T; Marinina, J; Orza, D; Storozhuk, E; Utkin, I; Vouros, P | 1 |
| Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL; Zalma, A | 1 |
| Damle, BD; Kaul, S; Knupp, C; Mummaneni, V | 1 |
| Back, DJ; Eagling, VA; Whitcombe, IW; Wiltshire, H | 1 |
| Gundu, J; Machavaram, KK; Yamsani, MR | 1 |
| Innocenti, F; Ramirez, J; Ratain, MJ; Yong, WP | 1 |
| Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H | 1 |
| Abay, E; Calitz, C; Gouws, C; Hamman, J; Steenekamp, J; Viljoen, J; Wiesner, L | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
1 review(s) available for ketoconazole and indinavir sulfate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ketoconazole and indinavir sulfate
| Article | Year |
|---|---|
Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.
Topics: Absorption; Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Antimetabolites; Capsules; Chemistry, Pharmaceutical; Ciprofloxacin; Cross-Over Studies; Didanosine; Drug Interactions; Drug Tolerance; Female; HIV Protease Inhibitors; Humans; Indinavir; Ketoconazole; Male; Middle Aged | 2002 |
28 other study(ies) available for ketoconazole and indinavir sulfate
| Article | Year |
|---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Caco-2 Cells; Dibenzocycloheptenes; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Mice; Quinolines; Testis | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Kinetics; Ligands; Models, Chemical; Pharmaceutical Preparations; Protein Binding; Recombinant Proteins; Spectrum Analysis; Thermodynamics; Titrimetry | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Topics: Anti-Bacterial Agents; Antifungal Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; HIV Protease Inhibitors; Humans; Hydroxylation; Indinavir; Isoenzymes; Ketoconazole; Microsomes, Liver; Mixed Function Oxygenases; Troleandomycin | 1996 |
Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Topics: Anti-HIV Agents; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Histamine H1 Antagonists; HIV Protease Inhibitors; Humans; Indinavir; Intestine, Small; Ketoconazole; Microsomes; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Saquinavir; Terfenadine | 1997 |
Determination of an in vivo metabolite of a human immunodeficiency virus protease-inhibitor in human plasma by high-performance liquid chromatography with tandem mass spectrometry.
Topics: Antifungal Agents; Chromatography, High Pressure Liquid; Circadian Rhythm; HIV Protease Inhibitors; Humans; Indinavir; Ketoconazole; Linear Models; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity | 1997 |
Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Topics: Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Mucosa; Ketoconazole; Kinetics; Microsomes; Mixed Function Oxygenases; Ritonavir | 1998 |
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Topics: Antidepressive Agents, Second-Generation; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Microsomes, Liver; Nelfinavir; Oxidoreductases, N-Demethylating; Piperazines; Ritonavir; Saquinavir; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Trazodone | 2000 |
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Female; Gene Expression; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Ketoconazole; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Butyrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Doxorubicin; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Etoposide; Indinavir; Infusions, Intravenous; Isoenzymes; Ketoconazole; Male; Nitrendipine; Quinidine; Rats; Rats, Wistar; Rifampin; Sulfobromophthalein | 2004 |
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Topics: Camptothecin; Dose-Response Relationship, Drug; Glucuronates; Glucuronosyltransferase; Hepatocytes; Humans; Indinavir; Irinotecan; Isoenzymes; Ketoconazole; Kinetics; Microsomes, Liver; Substrate Specificity | 2005 |
A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Topics: Area Under Curve; Cryopreservation; Cytochrome P-450 Enzyme System; Desipramine; Drug Interactions; Hepatocytes; Humans; Indinavir; Ketoconazole; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests; Quinidine; Technology, Pharmaceutical; Terfenadine | 2008 |
Herb-Drug Pharmacokinetic Interactions: Transport and Metabolism of Indinavir in the Presence of Selected Herbal Products.
Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Line, Tumor; Crotalid Venoms; Cytochrome P-450 CYP3A; Herb-Drug Interactions; Humans; Indinavir; Ketoconazole; Plant Extracts; Verapamil | 2015 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |